3rd Quarter - Report

WYETH for WYETH

Firm
Client
Income
—
Expenses
$756,650
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement Importation of FDA-approved pharmaceuticals

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —

Contacted: Executive Office of the President (EOP); Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Natl Security Agency (NSA); Food & Drug Administration (FDA); Justice, Dept of (DOJ); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Office of the Vice President of the United States; U.S. Trade Representative (USTR); Treasury, Dept of; State, Dept of (DOS)

Taxation/Internal Revenue Code TAX

Taxation of International Operations of U.S. corporations generally R&D tax credit Taxation of Deferred Compensation Plans Foreign tax credit legislation; Homeland investment legislation

LobbyistCovered position, as disclosed
LEO C JARDOT —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Justice, Dept of (DOJ); SENATE; Treasury, Dept of; Natl Security Agency (NSA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); White House Office; Office of the Vice President of the United States; Natl Security Council (NSC); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement H.R. 1908 Patent Reform Act of 2007 S. 1145 Patent Reform Act of 2007

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —

Contacted: Executive Office of the President (EOP); Natl Security Council (NSC); State, Dept of (DOS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Security Agency (NSA); White House Office; Justice, Dept of (DOJ); U.S. Trade Representative (USTR); Treasury, Dept of; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1145 (110th), H.R. 1908 (110th)

Health Issues HCR

Vaccine Injury Compensation Program Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; HR 3610 HR 5629 Childhood immunizations Dietary supplement issues Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 Drug compounding Alzheimer's care Comparative effectiveness - S.3408 - Comparative Effectiveness Research Act of 2008 S. 1695 Biologics Price Competition and Innovation Act of 2007 H.R. 1812 - Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act Pediatric Studies and Trials Drug Safety/Clinical Trials H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life Saving Medicine Act, Follow-on Biologics S. 1505 - Affordable Biologics for Consumers Act H.R. 3610 - Food and Drug Import Safety Act of 2007 S.2029 - Vaccine Safety and Payment Health care issues Drug approvals Reimbursement rates S. 334 The Healthy Americans Act H.Con.Res. 342 (BHRT) FDA Pre-emption S.3613, H.R. 7114 - Independence at Home Act S.3409-Drug and Device Accountability Act of 2008 Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Hormone replacement therapies

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Natl Security Council (NSC); White House Office; State, Dept of (DOS); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Security Agency (NSA); Office of the Vice President of the United States; Treasury, Dept of; Health & Human Services, Dept of (HHS); Justice, Dept of (DOJ)

Bills named: H.R. 7114 (110th), H.R. 1956 (110th), H.Con.Res. 342 (110th), S. 623 (110th), S. 1695 (110th), H.R. 5629 (110th), S. 2029 (110th), S. 334 (110th), H.R. 1812 (110th), S. 3613 (110th), H.R. 1038 (110th), S. 3409 (110th), S. 1505 (110th), H.R. 3610 (110th), S. 3408 (110th)

Medicare/Medicaid MMM

Vaccines Medicare chronic disease coverage Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Medicare coverage of pharmaceuticals, Medicare Part D Issues relating to Medicaid reimbursement for drugs/biologics in Title VI of S.1932-the Deficit Reduction Act of 2005 Pediatric Exclusivity H.R. 4 - Medicare Prescription Drug Price Negotiation Act H.R. 3162 - Children's Health and Medicare Protection Act of 2007 S.1893/H.R. 976 - Children's Health Insurance Progam Reauthorization Act of 2007 S. 2499 - Medicare, Medicaid and SCHIP Extension Act of 2007 Chronic care out of pocket costs S. 2029 - Physician Payments Sunshine Act of 2007 HR 5605 - Physician Payments Sunshine Act of 2007 HR 2185 - Enhanced Healthcare Value for All Act Medicare Prescription Drug Benefit Medicaid drug rebate Medicare Physician Reimbursement package Medicare and Medicaid Drug Reimbursement Medicaid Rebate Medicaid Part D Non-Interference H.R. 6331/S.3101 - Medicare Improvements for Patients and Providers Act of 2008 S.3118 - Preserving Access to Medicare Act of 2008 S.3613, H.R. 7114 - Independence at Home Act

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Natl Security Agency (NSA); Health & Human Services, Dept of (HHS); Office of the Vice President of the United States; Natl Security Council (NSC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Treasury, Dept of; Food & Drug Administration (FDA); U.S. Trade Representative (USTR); SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS); Justice, Dept of (DOJ)

Bills named: S. 2499 (110th), H.R. 6331 (110th), S. 3613 (110th), H.R. 7114 (110th), S. 1893 (110th), S. 3101 (110th), H.R. 5605 (110th), H.R. 976 (110th), H.R. 3162 (110th), S. 3118 (110th), H.R. 4 (110th), S. 1932 (110th), H.R. 2185 (110th), S. 2029 (110th)

Budget/Appropriations BUD

Pharmaceutical drug importation; Labor HHS Appropriations; Medicare and Medicaid Drug Reimbursement S.Con.Res 70/H.Con.Res 312 - FY 2009 Budget Resolution H.Res. 1190/S.Con.Res.70/H.Con.Res. 312 - FY 2009 Budget Resolution

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: State, Dept of (DOS); Treasury, Dept of; White House Office; Natl Security Agency (NSA); SENATE; Justice, Dept of (DOJ); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Natl Security Council (NSC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Office of the Vice President of the United States

Bills named: H.Res. 1190 (110th), S.Con.Res. 70 (110th), H.Con.Res. 312 (110th)

Consumer Issues/Safety/Products CSP

FDA reform proposals; Pseudoephedrine H.R. 970 DXM Distribution Act S. 1378 DXM Distribution Act S. 2274 Dextromethorphan Abuse Reduction Act Monograph System Reform Proposal S. 2274 DXM Abuse Reduction Act

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: SENATE; State, Dept of (DOS); Food & Drug Administration (FDA); Natl Security Council (NSC); U.S. Trade Representative (USTR); Executive Office of the President (EOP); Treasury, Dept of; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); White House Office; Health & Human Services, Dept of (HHS); Justice, Dept of (DOJ); Natl Security Agency (NSA); HOUSE OF REPRESENTATIVES

Bills named: S. 2274 (110th), H.R. 970 (110th), S. 1378 (110th)

Pharmacy PHA

H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007 S. 623/HR 1038 - Access to Life-Saving Medicine Act, Follow-on Biologics S.1695 - Biologics Price Competition and Innovation Act of 2007 S.1505- Affordable Biologics for Consumers Act H.R. 5629 - "Pathway for Biosimilars Act" H.R. 3610 - Food and Drug Import Safety Act of 2007 S.3409 - Drug and Device Accountability Act of 2008

LobbyistCovered position, as disclosed
LEO C JARDOT —
BRONWEN KAYE —
JULIE RABINOWITZ —
ANGELA WALKER RIEMER —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Office of the Vice President of the United States; Food & Drug Administration (FDA); SENATE; Natl Security Council (NSC); Executive Office of the President (EOP); Natl Security Agency (NSA); Justice, Dept of (DOJ); Treasury, Dept of; HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Bills named: S. 1505 (110th), S. 1695 (110th), H.R. 3610 (110th), H.R. 1956 (110th), S. 623 (110th), H.R. 5629 (110th), H.R. 1038 (110th), S. 3409 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.